THE WOODLANDS, Texas, Dec. 3 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. announces the following Webcast:
http://www.lexpharma.comhttp://www.videonewswire.com/event.asp?id=44188
If you are unable to participate during the live Webcast, the call will be archived on the Web site, http://www.lexpharma.com, until December 12, 2007.
Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.
CONTACT: Bobbie Faulkner of Lexicon Pharmaceuticals, +1-281-863-3503
Web site: http://www.lexpharma.com/
